Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study of Curcumin C-3 Complex, the Prototypal Epigenetic Modulator, as an Augmentation Strategy to Antipsychotic Therapy,for Improving Negative Symptoms and Cognition in Schizophrenia

NCT01875822 is registered in ClinicalTrials.gov with Woodbury, Michel, M.D. as lead sponsor.

NCT NCT01875822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01875822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study of Curcumin C-3 Complex, the Prototypal Epigenetic Modulator, as an Augmentation Strategy to Antipsychotic Therapy,for Improving Negative Symptoms and Cognition in Schizophrenia
Lead sponsor
Woodbury, Michel, M.D.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2009
Completion date
May 31, 2012
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, schizoaffective disorder, schizophrenia